Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Breast cancer, early stage

4309 - Randomized Trial of Lisinopril or Carvedilol for the Prevention of Cardiotoxicity in Patients with Early Stage HER2-Positive Breast Cancer Receiving Trastuzumab


20 Oct 2018


Poster Discussion session - Breast cancer, early stage


Management of Systemic Therapy Toxicities;  Supportive Care and Symptom Management;  Targeted Therapy

Tumour Site

Breast Cancer


Pamela Munster


Annals of Oncology (2018) 29 (suppl_8): viii58-viii86. 10.1093/annonc/mdy270


P.N. Munster1, J. Krischer2, R. Tamura2, L. Bello-Matricaria2, A. Fink2, W. McCaskill-Stevens3, M. Guglin4

Author affiliations

  • 1 Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, 94115 - San Francisco/US
  • 2 Health Informatics Institute, University of South Florida, 33612 - Tampa/US
  • 3 Prevention, National Cancer Institute Div. Cancer Treatment, 20852-7426 - Rockville/US
  • 4 Cardiology, University of Kentucky, 40536 - Lexington/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4309


Trastuzumab is an integral part of therapy for patients with HER2-positive breast cancer. Yet, cardiac side effects, particularly in patients who receive anthracyclines require frequent monitoring and result in dose interruptions and discontinuation of trastuzumab. Prophylactic use of angiotensin converting enzyme inhibitors or beta blockers may prevent cardiotoxicity associated with chemotherapy and trastuzumab.


In a large prospective double-blind, placebo-controlled trial, the rates of pre-specified cardiotoxicity and trastuzumab interruptions were evaluated in patients with early stage HER2 positive breast cancer treated with one year of trastuzumab. Patients were randomized to simultaneously receive either the ACE inhibitor, lisinopril, or beta-blocker, carvedilol, or placebo and were stratified by anthracycline use.


The study included 468 eligible patients (median age:51, BMI:27 kg/m2, baseline systolic BP: 126mmHg and LVEF: 63 ± 6.29%) from 127 community-based practices. Both interventions reduced trastuzumab interruptions (p = 0.01). For patients receiving an anthracycline, cardiac event rates were higher in the placebo group (47%), compared to lisinopril (37%), and carvedilol (31%). Interruptions of trastuzumab were required in 23% patients on lisinopril and 20% on carvedilol compared to 40% on placebo (p = 0.007). Changes in LVEF from baseline (least square means, SE) were significantly reduced with both carvedilol (-4.5 (0.8), p = 0.008, and lisinopril (-4.0 (0.8), p = 0.002) than placebo, (-7.7 (0.8). Cardiotoxicity-free survival was longer on both carvedilol (hazard ratio 0.49, 95% confidence intervals 0.27, 0.89, p = 0.009) or lisinopril (HR 0.53, CI 0.30, 0.94, p = 0.015). Cardiac events for patients treated with non-anthracycline containing regimens were similar for all groups with no difference in number of trastuzumab interruptions.


Both lisinopril and carvedilol prevented cardiotoxicity in patients with HER2-positive breast cancer treated with trastuzumab and anthracyclines. The use of lisinopril or carvedilol should be considered to offset cardiac events and to minimize interruptions of trastuzumab.

Clinical trial identification


Legal entity responsible for the study

National Cancer Institute, Community Oncology and Prevention Trials Research Group, Rockville, MD.


National Cancer Institute, Community Oncology and Prevention Trials Research Group, Rockville, MD.

Editorial Acknowledgement


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.